Skip to content

Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers

Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00748956
Acronym
NPY
Enrollment
10
Registered
2008-09-09
Start date
2010-01-31
Completion date
2012-01-31
Last updated
2017-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders, Mood Disorder

Keywords

Mood Disorder, Anxiety Disorders

Brief summary

There is growing evidence that neuropeptides act as neuronal messengers in the brain and have diverse functions that may include the regulation of mood and behavior. For example, neuropeptide Y (NPY) is thought to play a role in the adaptive stress response. The therapeutic application of neuropeptides for psychiatric disorders has been limited by difficult and unreliable penetration of the blood-brain barrier (BBB). However, recent data suggest that intranasal administration may provide a means of effectively delivering some of these neuropeptides to the brain. Thus far it is unclear if this is the case for NPY. The aims of this project are: 1. To evaluate, in 15 healthy male volunteers aged 25-45, the effect of intranasal NPY administration (0, 50 and 100 nmol) on its levels in cerebrospinal fluid (CSF), measured by means of lumbar puncture using an intraspinal catheter between L4 and L5, and in plasma, measured using an intravenous catheter in the forearm. One of the three treatments will be administered to each participant in a double-blind fashion. The 0 nmol condition will serve as the placebo control. 2. To test the effect of intranasal NPY administration on mood and anxiety.

Detailed description

There is growing evidence that neuropeptides, including neuropeptide Y (NPY), act as neuronal messengers in the brain and have diverse neurobehavioral functions. Their therapeutic application for psychiatric disorders has been limited, however, by difficult and unreliable penetration of the blood-brain barrier (BBB). The BBB has prevented the use of many therapeutic agents for treating central nervous system (CNS) disorders. Several molecules have successfully been administered through intranasal delivery, however, thanks to the unique connection that the nerves involved in sensing odors and chemicals provide between the CNS and its environment. NPY, the most abundant peptide in the mammalian brain, is co-localized with norepinephrine in sympathetic nerve fibers and has been of longstanding interest to our research group (Morgan et al., 2002; Morgan et al., 2003; Morgan et al., 2001; Morgan et al., 2000; Rasmusson et al., 2000; Rasmusson et al., 1998) because of its potential role in modulating mood and anxiety. NPY has been implicated as factor in the adaptive stress response (Thorsell et al., 1999), and has been shown to impact the consolidation of fear-related memories after shock (Flood et al., 1989). Clinically, lower plasma NPY levels have been correlated with greater psychological distress, increased symptoms of dissociation, and poorer performance among active duty military personnel. Acute stress in humans has been found to elicit NPY release, in a manner parallel to the changes in cortisol and norepinephrine that are usually seen, with a blunting of the plasma NPY response in response to yohimbine (Morgan et al., 2002). Baseline NPY levels in combat veterans with PTSD are reduced compared to healthy non-traumatized individuals (Rasmusson et al., 2000). Another study found that repeated exposure to traumatic stress, rather than the presence of PTSD or PTSD-type symptoms, is associated with a reduction in baseline plasma NPY (Morgan et al., 2003). A recent report found deceased CSF concentrations of NPY in patients with treatment resistant unipolar major depression (Heilig et al 2004). In summary, there has been suggestion from studies in patients with anxiety and mood disorders as well as healthy volunteers of an abnormal regulation of this peptide. In this study, we will evaluate intranasal administration of NPY in healthy male volunteers ages 25-45 using a specialized delivery device. Pending the initial feasibility and tolerability in healthy volunteers, future protocols will examine the effect of intranasal NPY administration in patients with disorders such as PTSD, major depression, panic disorder, and social anxiety disorder.

Interventions

DRUGLow dose NPY

50nmol, administered intranasally

DRUGHigh dose NPY

100nmol administered intranasally

DRUGPlacebo

placebo comparator (0nmol)) administered intranasally

Sponsors

Dennis Charney
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
25 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Men aged 25-45. * No history of Axis I disorder as defined in the DSM-IV other than past nicotine abuse or dependence or adjustment disorder.

Exclusion criteria

* Nicotine or caffeine abuse or dependence within the preceding 3 months. * History or complaint of nasal disorders or allergies. * Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic. * Significant obesity (BMI \> 30), scoliosis, spinal stenosis or a history of lumbosacral laminectomy. * Clinically significant abnormal findings of laboratory parameters, physical examination, or ECG. * Current use of any medications that have effects on CNS function. * Prior sinonasal surgery, or significant nasal polyps as determined by nasal endoscopy.

Design outcomes

Primary

MeasureTime frameDescription
Levels of NPY in CSFon study day 2Levels of Neuropeptide Y in the cerebrospinal fluid

Secondary

MeasureTime frameDescription
Systematic Assessment of Treatment-Emergent Effects (SAFTEE)on study day 2Number of participants with serious adverse events
Appetite Scaleon study day 2measure in 2 hours post intranasal administration
Post-sleep Questionnaireon study day 2measure in the morning
Quick Inventory of Depressive Symptoms (QIDS)on study day 2measure in 2 hours post intranasal administration
Profile of Mood States (POMS)on study day 2measure in 2 hours post intranasal administration and on the next morning

Countries

United States

Participant flow

Participants by arm

ArmCount
Low Dose NPY
Low dose, Receive 50 nmol dose of NPY Low dose NPY: 50nmol, administered intranasally
0
High Dose NPY
High Dose, Receive 100 nmol dose of NPY High dose NPY: 100nmol administered intranasally
5
Placebo
Placebo comparator Placebo: placebo comparator (0nmol)) administered intranasally
5
Total10

Baseline characteristics

CharacteristicHigh Dose NPYPlaceboTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
5 Participants5 Participants10 Participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
5 Participants5 Participants10 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 00 / 50 / 5
other
Total, other adverse events
0 / 00 / 50 / 5
serious
Total, serious adverse events
0 / 01 / 51 / 5

Outcome results

Primary

Levels of NPY in CSF

Levels of Neuropeptide Y in the cerebrospinal fluid

Time frame: on study day 2

ArmMeasureValue (MEAN)Dispersion
High Dose NPYLevels of NPY in CSF329.4 pg/mLStandard Deviation 119.9
PlaceboLevels of NPY in CSF351.0 pg/mLStandard Deviation 41.6
Secondary

Appetite Scale

measure in 2 hours post intranasal administration

Time frame: on study day 2

Population: data not collected

Secondary

Post-sleep Questionnaire

measure in the morning

Time frame: on study day 2

Population: data not collected

Secondary

Profile of Mood States (POMS)

measure in 2 hours post intranasal administration and on the next morning

Time frame: on study day 2

Population: data not collected

Secondary

Quick Inventory of Depressive Symptoms (QIDS)

measure in 2 hours post intranasal administration

Time frame: on study day 2

Population: data not collected

Secondary

Systematic Assessment of Treatment-Emergent Effects (SAFTEE)

Number of participants with serious adverse events

Time frame: on study day 2

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Low Dose NPYSystematic Assessment of Treatment-Emergent Effects (SAFTEE)0 Participants
High Dose NPYSystematic Assessment of Treatment-Emergent Effects (SAFTEE)0 Participants
PlaceboSystematic Assessment of Treatment-Emergent Effects (SAFTEE)0 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026